Stay updated on ADXS11-001 & MEDI4736 Combo in HPV+ Cancer Clinical Trial
Sign up to get notified when there's something new on the ADXS11-001 & MEDI4736 Combo in HPV+ Cancer Clinical Trial page.

Latest updates to the ADXS11-001 & MEDI4736 Combo in HPV+ Cancer Clinical Trial page
- Check4 days agoChange Detected- Added a comprehensive Locations section listing study sites by state (California, Connecticut, Florida, Illinois, Kentucky, Maryland, Michigan, Nebraska, New York, Ohio, Oklahoma, Tennessee, Wisconsin) and a Revision: v3.3.3.SummaryDifference1%

- Check12 days agoNo Change Detected
- Check19 days agoNo Change Detected
- Check33 days agoChange DetectedThe Publications section text was updated to clarify that publications are provided voluntarily by the person entering information and relate to the study results, and the revision label changed from v3.2.0 to v3.3.2.SummaryDifference0.1%

- Check40 days agoChange DetectedThe page removes a general government funding status notice related to NIH operations and the NIH Clinical Center. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check55 days agoChange DetectedThe screenshots show the same Study Details page with identical content and structure; no new or removed information affecting the page’s purpose.SummaryDifference0.4%

- Check83 days agoChange DetectedAdded a prominent government-operating-status notice and new version tag (v3.2.0), replacing the previous v3.1.0. The page now informs users about potential delays and where to check status.SummaryDifference2%

- Check91 days agoChange DetectedVersion update: from v3.0.2 to v3.1.0. The core page content shifts to the newer release identifier; no other substantive content changes are indicated.SummaryDifference0.1%

Stay in the know with updates to ADXS11-001 & MEDI4736 Combo in HPV+ Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ADXS11-001 & MEDI4736 Combo in HPV+ Cancer Clinical Trial page.